Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Summary Background Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. Aim To evaluate the effect of the glucagon‐like peptide‐1 analogue, se...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2019-07, Vol.50 (2), p.193-203 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 2 |
| container_start_page | 193 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 50 |
| creator | Newsome, Philip Francque, Sven Harrison, Stephen Ratziu, Vlad Van Gaal, Luc Calanna, Salvatore Hansen, Morten Linder, Martin Sanyal, Arun |
| description | Summary
Background
Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment.
Aim
To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD.
Methods
Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight.
Results
Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P |
| doi_str_mv | 10.1111/apt.15316 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6617813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248383179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-505b57ee4abbf4b93f92b4e8bd2c93dd04dec49874dbecd23fe1fd03c4cef0613</originalsourceid><addsrcrecordid>eNp1kUtv1TAQRi0EopfCgj-ALLGBRXr9ipNskKqqPKRKsChry49x60sSX2ynVfj1uNxSARLezMJnjmbmQ-glJSe0vq3elxPaciofoQ3lsm0Y4fIx2hAmh4b1lB-hZznvCCGyI-wpOuKUCcllv0Hp3HuwBUePM0z6alxKcIDjjMdwAwnD_GOdIGM9Ozzp9A1SvmPD7Ec9TbqESoYZ58Xsqibj21CucVn3gBl2QRsoh-ZtTDgayKGsz9ETr8cML-7rMfr6_vzy7GNz8fnDp7PTi8YKwWXTkta0HYDQxnhhBu4HZgT0xjE7cOeIcGDF0HfCGbCOcQ_UO8KtsOCJpPwYvTt494uZwFmYS9Kj2qdQF1lV1EH9_TOHa3UVb5SUtKtHq4I394IUvy-Qi5pCtjCOeoa4ZMWY6HnPaTdU9PU_6C4uaa7rKcY57enQdaxSbw-UTTHnBP5hGErUXZKqJql-JVnZV39O_0D-jq4C2wNwG0ZY_29Sp18uD8qfu-aq1Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331819772</pqid></control><display><type>article</type><title>Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Newsome, Philip ; Francque, Sven ; Harrison, Stephen ; Ratziu, Vlad ; Van Gaal, Luc ; Calanna, Salvatore ; Hansen, Morten ; Linder, Martin ; Sanyal, Arun</creator><creatorcontrib>Newsome, Philip ; Francque, Sven ; Harrison, Stephen ; Ratziu, Vlad ; Van Gaal, Luc ; Calanna, Salvatore ; Hansen, Morten ; Linder, Martin ; Sanyal, Arun</creatorcontrib><description>Summary
Background
Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment.
Aim
To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD.
Methods
Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight.
Results
Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change.
Conclusions
Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.15316</identifier><identifier>PMID: 31246368</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alanine ; Alanine transaminase ; Alanine Transaminase - metabolism ; Biomarkers - metabolism ; Body weight ; Body Weight - drug effects ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Clinical trials ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Double-Blind Method ; Fatty liver ; Female ; Glucagon ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptides - pharmacology ; Glucagon-Like Peptides - therapeutic use ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity ; Inflammation - complications ; Inflammation - drug therapy ; Inflammation - metabolism ; Liver ; Liver - drug effects ; Liver - enzymology ; Liver - metabolism ; Liver diseases ; Male ; Middle Aged ; Multicenter Studies as Topic - statistics & numerical data ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - metabolism ; Non-alcoholic Fatty Liver Disease - prevention & control ; Obesity ; Obesity - complications ; Obesity - drug therapy ; Obesity - metabolism ; Original ; Peptides ; Randomized Controlled Trials as Topic - statistics & numerical data ; Retrospective Studies ; Statistical analysis ; Weight control ; Weight Reduction Programs ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2019-07, Vol.50 (2), p.193-203</ispartof><rights>2019 The Authors. published by John Wiley & Sons Ltd</rights><rights>2019 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-505b57ee4abbf4b93f92b4e8bd2c93dd04dec49874dbecd23fe1fd03c4cef0613</citedby><cites>FETCH-LOGICAL-c4436-505b57ee4abbf4b93f92b4e8bd2c93dd04dec49874dbecd23fe1fd03c4cef0613</cites><orcidid>0000-0001-8682-5748 ; 0000-0001-6085-3652</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.15316$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.15316$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31246368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newsome, Philip</creatorcontrib><creatorcontrib>Francque, Sven</creatorcontrib><creatorcontrib>Harrison, Stephen</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Van Gaal, Luc</creatorcontrib><creatorcontrib>Calanna, Salvatore</creatorcontrib><creatorcontrib>Hansen, Morten</creatorcontrib><creatorcontrib>Linder, Martin</creatorcontrib><creatorcontrib>Sanyal, Arun</creatorcontrib><title>Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment.
Aim
To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD.
Methods
Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight.
Results
Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change.
Conclusions
Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Alanine Transaminase - metabolism</subject><subject>Biomarkers - metabolism</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Clinical trials</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Double-Blind Method</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Glucagon</subject><subject>Glucagon-Like Peptide 1 - analogs & derivatives</subject><subject>Glucagon-Like Peptides - pharmacology</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity</subject><subject>Inflammation - complications</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - enzymology</subject><subject>Liver - metabolism</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic - statistics & numerical data</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - metabolism</subject><subject>Non-alcoholic Fatty Liver Disease - prevention & control</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Original</subject><subject>Peptides</subject><subject>Randomized Controlled Trials as Topic - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Weight control</subject><subject>Weight Reduction Programs</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kUtv1TAQRi0EopfCgj-ALLGBRXr9ipNskKqqPKRKsChry49x60sSX2ynVfj1uNxSARLezMJnjmbmQ-glJSe0vq3elxPaciofoQ3lsm0Y4fIx2hAmh4b1lB-hZznvCCGyI-wpOuKUCcllv0Hp3HuwBUePM0z6alxKcIDjjMdwAwnD_GOdIGM9Ozzp9A1SvmPD7Ec9TbqESoYZ58Xsqibj21CucVn3gBl2QRsoh-ZtTDgayKGsz9ETr8cML-7rMfr6_vzy7GNz8fnDp7PTi8YKwWXTkta0HYDQxnhhBu4HZgT0xjE7cOeIcGDF0HfCGbCOcQ_UO8KtsOCJpPwYvTt494uZwFmYS9Kj2qdQF1lV1EH9_TOHa3UVb5SUtKtHq4I394IUvy-Qi5pCtjCOeoa4ZMWY6HnPaTdU9PU_6C4uaa7rKcY57enQdaxSbw-UTTHnBP5hGErUXZKqJql-JVnZV39O_0D-jq4C2wNwG0ZY_29Sp18uD8qfu-aq1Q</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Newsome, Philip</creator><creator>Francque, Sven</creator><creator>Harrison, Stephen</creator><creator>Ratziu, Vlad</creator><creator>Van Gaal, Luc</creator><creator>Calanna, Salvatore</creator><creator>Hansen, Morten</creator><creator>Linder, Martin</creator><creator>Sanyal, Arun</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8682-5748</orcidid><orcidid>https://orcid.org/0000-0001-6085-3652</orcidid></search><sort><creationdate>201907</creationdate><title>Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity</title><author>Newsome, Philip ; Francque, Sven ; Harrison, Stephen ; Ratziu, Vlad ; Van Gaal, Luc ; Calanna, Salvatore ; Hansen, Morten ; Linder, Martin ; Sanyal, Arun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-505b57ee4abbf4b93f92b4e8bd2c93dd04dec49874dbecd23fe1fd03c4cef0613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Alanine Transaminase - metabolism</topic><topic>Biomarkers - metabolism</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Clinical trials</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Double-Blind Method</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Glucagon</topic><topic>Glucagon-Like Peptide 1 - analogs & derivatives</topic><topic>Glucagon-Like Peptides - pharmacology</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity</topic><topic>Inflammation - complications</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - enzymology</topic><topic>Liver - metabolism</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic - statistics & numerical data</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - metabolism</topic><topic>Non-alcoholic Fatty Liver Disease - prevention & control</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Original</topic><topic>Peptides</topic><topic>Randomized Controlled Trials as Topic - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Weight control</topic><topic>Weight Reduction Programs</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newsome, Philip</creatorcontrib><creatorcontrib>Francque, Sven</creatorcontrib><creatorcontrib>Harrison, Stephen</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Van Gaal, Luc</creatorcontrib><creatorcontrib>Calanna, Salvatore</creatorcontrib><creatorcontrib>Hansen, Morten</creatorcontrib><creatorcontrib>Linder, Martin</creatorcontrib><creatorcontrib>Sanyal, Arun</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newsome, Philip</au><au>Francque, Sven</au><au>Harrison, Stephen</au><au>Ratziu, Vlad</au><au>Van Gaal, Luc</au><au>Calanna, Salvatore</au><au>Hansen, Morten</au><au>Linder, Martin</au><au>Sanyal, Arun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2019-07</date><risdate>2019</risdate><volume>50</volume><issue>2</issue><spage>193</spage><epage>203</epage><pages>193-203</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment.
Aim
To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD.
Methods
Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight.
Results
Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change.
Conclusions
Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31246368</pmid><doi>10.1111/apt.15316</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8682-5748</orcidid><orcidid>https://orcid.org/0000-0001-6085-3652</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2019-07, Vol.50 (2), p.193-203 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6617813 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Adolescent Adult Aged Aged, 80 and over Alanine Alanine transaminase Alanine Transaminase - metabolism Biomarkers - metabolism Body weight Body Weight - drug effects Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Clinical trials Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Double-Blind Method Fatty liver Female Glucagon Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptides - pharmacology Glucagon-Like Peptides - therapeutic use Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity Inflammation - complications Inflammation - drug therapy Inflammation - metabolism Liver Liver - drug effects Liver - enzymology Liver - metabolism Liver diseases Male Middle Aged Multicenter Studies as Topic - statistics & numerical data Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - prevention & control Obesity Obesity - complications Obesity - drug therapy Obesity - metabolism Original Peptides Randomized Controlled Trials as Topic - statistics & numerical data Retrospective Studies Statistical analysis Weight control Weight Reduction Programs Young Adult |
| title | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A55%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20semaglutide%20on%20liver%20enzymes%20and%20markers%20of%20inflammation%20in%20subjects%20with%20type%202%20diabetes%20and/or%20obesity&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Newsome,%20Philip&rft.date=2019-07&rft.volume=50&rft.issue=2&rft.spage=193&rft.epage=203&rft.pages=193-203&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.15316&rft_dat=%3Cproquest_pubme%3E2248383179%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331819772&rft_id=info:pmid/31246368&rfr_iscdi=true |